EP3920990A1 - Biodegradierbare membran - Google Patents
Biodegradierbare membranInfo
- Publication number
- EP3920990A1 EP3920990A1 EP20703734.2A EP20703734A EP3920990A1 EP 3920990 A1 EP3920990 A1 EP 3920990A1 EP 20703734 A EP20703734 A EP 20703734A EP 3920990 A1 EP3920990 A1 EP 3920990A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fibers
- membrane
- mixture
- group
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/028—Other inorganic materials not covered by A61L31/022 - A61L31/026
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/003—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor characterised by the choice of material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/755—Membranes, diaphragms
Definitions
- the present invention relates to a biodegradable membrane based on an organic-inorganic hybrid polymer and a method for its production.
- Adhesions are scarred strands of connective tissue that create an unnatural connection between different body tissues. They can be either congenital or acquired. Acquired adhesions are usually the result of an operation. But they can also develop in inflammatory diseases of the abdomen or in the context of endometriosis (disease of the uterine lining).
- Postoperative adhesions occur despite the best possible surgical technique and tissue-sparing surgical methods (such as minimally invasive interventions). They only cause discomfort in exceptional cases, but can then significantly affect the health and quality of life of those affected. pregnant. Adhesions that accompany operations in the abdominal cavity and surgical interventions in the uterus (e.g. excretion or removal of myomas) can be the reason for unwanted childlessness, chronic pelvic pain or narrowing and congestion of the intestine.
- adhesions are only a natural reaction of wound healing, e.g. an injury to the peritoneum and / or organs. According to studies, they are found after 67 to 93% of all operations in which the peritoneum has been opened (G. Pados et al., Prevention of intra peritoneal adhesions in gynaecological surgery: theory and evidence, in Reproductive BioMedicine Online (2010) 21, 290-303). Nevertheless, it can happen that organs of the abdominal and pelvic area, e.g. B. loops of intestine, anei nander or attached to the peritoneum or the fallopian tubes and ovaries are tied and fixed in an unnatural way.
- organs of the abdominal and pelvic area e.g. B. loops of intestine, anei nander or attached to the peritoneum or the fallopian tubes and ovaries are tied and fixed in an unnatural way.
- No. 7,172,765 B2 describes, for example, a method for reducing operative adhesions with the aid of a biodegradable membrane which consists of an electrospun fiber fabric without any filler or matrix material.
- the production of large areas or quantities of the membrane thus requires a lot of time.
- electrospinning usually uses solvents that are toxic to cells, which are then carefully must be removed.
- US Pat. No. 5,948,020 A likewise provides a bioresorbable membrane which can be inserted into human or animal tissue and there for some time prevents the undesired growth of other cells onto the tissue connected to the membrane.
- the membrane is made up of fibers and a polymer matrix.
- degradable organic polymers are used for the production of both the fibers and the matrix. The disadvantage of these is that they usually show the effect of shrinking on contact with physiological media and do not remain dimensionally stable during the degradation.
- the object of the present invention to provide a method with which the disadvantages known from the prior art are overcome and with which membranes can be produced in a simple manner that are biodegradable, but at least their barrier function Maintained over a period of three to seven days. Furthermore, the present invention was based on the task of providing a corresponding biodegradable membrane which at the same time has high dimensional stability and high flexibility.
- the process according to the invention for producing a biodegradable membrane based on an organic-inorganic hybrid polymer comprises the following process steps: Production of an inorganic sol by stirring a solution containing at least one aqueous solvent, an alkoxysilane and an acid at a temperature of at least 20 ° C (step a ); Converting the sol to a polymer-sol mixture by adding an end-group-functionalized, biodegradable organic polymer or by adding precursors of the polymer to the sol (step b); and applying the polymer-sol mixture to a front side of a film for Curing of the mixture to form a hybrid polymer layer (step c), a multiplicity of fibers being introduced into the mixture in an additional step d) before the mixture is cured.
- Biodegradable is understood to mean that the membrane degrades on permanent contact with a physiological solution.
- a buffered aqueous solution with a pH of 7.3 - 7.5 can be used as a physiological solution.
- an aqueous PBS solution containing 8.0 g / L NaCl, 0.2 g / L KCl, 1.42 g / L Na 2 HP0 4 and 0.27 g / L can be used to test the biodegradability KH 2 P0 4 contains .
- the method allows a membrane to be produced that is based on two main components.
- the first component is the organic inorganic hybrid polymer, which serves as the matrix material.
- the second component is the multitude of fibers that are embedded in the matrix. The properties of the two components surprisingly complement each other in such a way that the membrane resulting therefrom has a high tensile strength and at the same time a high degree of flexibility and flexibility.
- the organic-inorganic hybrid polymer is obtained either by adding an end-group-functionalized, biodegradable organic polymer or by adding precursors of the polymer to the sol. While the precursors of the polymer are low molecular weight oligomers that are only precondensed to a small degree, the polymer itself is a high molecular weight polymer.
- the membrane produced in this way does not shrink in the first few weeks despite permanent wetting with a physiological solution and the resulting progressive biodegradation. It initially retains its original dimensions. With a view to the use of the membrane as an adhesion barrier to avoid postoperative adhesions of various tissues, this prevents mechanical tensions from occurring during the healing process that could be perceived as unpleasant by the patient. Furthermore, the membrane produced by the method according to the invention has a dehesive effect after it has been applied to a cell tissue. This means that the membrane prevents neighboring cell tissue from growing.
- the process is also suitable for transfer to an industrial scale and for the production of larger quantities.
- the plurality of fibers are preferably introduced into the mixture in step d) by distributing fibers on the front side of the film before the mixture is applied (variant i) or by distributing the fibers on a surface of the mixture applied (variant ii).
- the fibers are particularly preferably aligned along a preferred direction or arranged in the form of a regular scrim or fabric.
- These process variants (i and ii) are suitable for producing a membrane in which the fibers are integrated into the hybrid polymer layer produced by curing the mixture.
- the decision as to whether the fibers should be aligned along a preferred direction or arranged in the form of a scrim or fabric should be made taking into account the later application. If it is to be expected that the mechanical stress on the membrane is increased in one direction, there are many arguments in favor of aligning the fibers in a preferred direction.
- Orientation in a preferred direction can be achieved, for example, by spinning the fibers. This can be achieved through the spinning process by placing the fibers in a directional manner. This can e.g. take place via a programmable traversing table that moves at a defined speed in the x and y directions
- steps c) and d) it is also possible to carry out steps c) and d) several times and in each case alternately in succession. This affects the thickness of the membrane, which can be increased by applying the polymer-sol mixture several times. In addition, the distribution of the fibers in the cross-section of the membrane can be influenced.
- the fibers are carried out for the first time in process steps c) and d) before application of the mixture on the film and in the second execution of process steps c) and d) only after application of the polymer-sol mixture, the fiber density is increased on both sides of the membrane on the surface, while it is Inside the membrane is lowered. This is due to the fact that the fibers cannot distribute themselves evenly due to the viscosity of the polymer-sol mixture. Other fiber density distributions are achieved if a different approach is taken.
- a layer of the polymer-sol mixture is applied to the film.
- the fibers are introduced before the mixture hardens.
- another layer of the polymer-sol mixture is applied. Fibers are no longer integrated into this layer.
- the solution in step a) can be stirred at a temperature of 20 to 50.degree. C., preferably from 50 to 45.degree. C., in particular 40.degree.
- a stirring time of at least 7 hours is preferred, particularly preferably at least 8 hours, in particular at least 18 hours.
- the mixture is applied in step c) by knife-coating or flooding of the front side of the film, the knife-coating preferably being carried out with the aid of a doctor blade, a spiral or a film-drawing device.
- the alkoxysilane can be selected from the group consisting of tetramethyl orthosilicate, tetraethyl orthosilicate, tetrapropyl orthosilicate, tetraisopropyl orthosilicate, tetrabutyl orthosilicate, and mixtures thereof.
- the end-group-functionalized, biodegradable organic polymer is preferably selected from the group consisting of end-group-functionalized polyesters, end-group-functionalized polyalcohols, end-group-functionalized polyoxazolines, end-group-functionalized polyanhydrides, end-group-functionalized group-functionalized polysaccharides, end-group-functionalized polyhydroxylalkanoates, end-group-functionalized proteins and mixtures thereof.
- the end-group-functionalized, biodegradable organic polymer is preferably an elastomer.
- the end group functionalization preferably consists of terminal hydroxyl groups,
- a well-suited end-group-functionalized, biodegradable organic polymer is silanized polycaprolactam (PCL).
- the end group functionalization of the organic polymer guarantees that it is at least partially linked covalently to the inorganic sol.
- the structure of the organic polymers is arbitrary. Hybrid polymers with linear organic polymers as well as with branched or star-shaped organic polymers can be formed.
- the solubility of the organic polymers is more important. It is preferred here that the organic polymers dissolve well in aqueous or alcoholic solution or in a mixture of water and alcohol, or can at least be finely dispersed therein.
- Biodegradable elastomers are particularly preferably used as organic polymers.
- the acid which is used in process step a) is a sulfonic acid, preferably methanesulfonic acid.
- the acid can also be a mineral acid, for example HCl, H 2 S0 4 , HN0 3 , Hl or H 3 P0 4 . Mixtures of the aforementioned acids are also possible.
- the production of the biodegradable membrane is also facilitated if the solution in step a) of the method has a pH between 1 and 7, preferably between 1 and 3.
- a suitable aqueous solvent is water or a mixture of water and an alcohol, tetrahydrofuran or toluene. Of these, the mixture of water and an alcohol, e.g. ethanol, is particularly recommended. Such a mixture makes it possible to manufacture the membrane without the use of solvents which are hazardous to health. Careful separation of solvent residues is therefore not necessary.
- the polymer in step b) of the process is preferably in a weight ratio of 0.1 to 10.0, particularly preferably from 0.5 to 8.0, in particular from 1.0 to 6.0, based on the mass of the in Step a) added sols prepared. In this way it is ensured that the weight fraction of the organic polymer in the hybrid polymer layer is at least 10% by weight, preferably at least 20% by weight. It is particularly preferred if the weight fraction of the organic polymer in the hybrid polymer layer is between 33 and 85% by weight.
- Biodegradable fibers of any kind can be used as fibers. They can be organic, inorganic or hybrid in nature. The length of the fibers can also vary, so continuous fibers, long fibers but also shorter fiber pieces can be integrated into the polymer-sol mixture.
- Polysaccharide fibers, polyhydroxyalkanoate fibers, protein fibers and mixtures thereof used preferably from the group consisting of silica gel fibers and Ti0 2 -containing fibers, the fibers particularly preferably in a proportion of a maximum of 50 wt .-%, very particularly preferably a maximum of 33 wt. -%, in particular a maximum of 25% by weight, based on the total mass of hybrid polymer layer and fibers are used.
- Silica gel fibers have the advantage that they are structurally very similar to the inorganic sol that is formed from the alkoxysilane and can therefore be easily integrated into the polymer-sol mixture.
- Particularly tear-resistant membranes are obtained when fibers with a tensile strength of at least 2800 MPa, preferably of at least
- 2950 MPa in particular of at least 3000 MPa, can be used in the method according to the invention.
- the fibers preferably have a diameter of 1 nm to 2 mm, preferably from 1 to 100 ⁇ m, in particular from 50 to 60 ⁇ m.
- the Fibers to fibers obtained via the electrospinning method preferably fibers obtained via the electrospinning method selected from the group consisting of silica gel fibers, Ti0 2 -containing fibers, polyester fibers, polyanhydride fibers, polysaccharide fibers, polyhydroxyalkanoate fibers, protein fibers and mixtures thereof. If silica gel is used as the material for these fibers, the fibers preferably have a diameter in the range from 100 nm to 5 miti, particularly preferably in the range from 500 nm to 2 miti.
- the membrane is detached from the front side of the film after a drying time of at least 30 minutes, the front side of the film preferably being adhesive and / or consisting of ethylene-tetrafluoroethylene copolymer.
- a particularly useful embodiment of the method from a medical point of view is achieved if at least one pharmacologically active compound is added in step a) or b) of the method or is used to impregnate the hybrid polymer layer after curing, the proportion of the pharmacologically active compound is chosen so that it is preferably from 1 to 20 wt .-% based on the total mass of
- Hybrid polymer layer and fibers are Hybrid polymer layer and fibers.
- Particularly suitable pharmacologically active compounds are antibiotics and substances that reduce scarring. These compounds can be released during the degradation of the membrane. They can either be encapsulated or integrated in the membrane in their pure form. Encapsulation can take place through the formation of micelles, liposomes with the aid of block copolymers or inorganic particulate systems such as mesoporous or microporous particles. If pharmacologically active compounds are integrated into the membrane, the temperature during manufacture must never exceed the decomposition temperature of the active ingredient.
- a membrane made of a biodegradable, organic, inorganic hybrid polymer and a large number of fibers is provided.
- the membrane can be decomposed and / or degraded by contacting it with a physiological solution, preferably an aqueous PBS solution containing NaCl, KCl, Na 2 HP0 4 and KH 2 P0 4 .
- a physiological solution preferably an aqueous PBS solution containing NaCl, KCl, Na 2 HP0 4 and KH 2 P0 4 .
- the membrane is particularly preferably degraded to at least 35% by weight of its total mass, preferably to at least 60% by weight of its total mass, within 64 days.
- the membrane according to the invention is preferably at least 10% by weight of the total mass, preferably at least 20% by weight of the total mass, particularly preferably at least 25% by weight of the total mass, decomposed and / or degraded.
- the membrane according to the invention is characterized in that it forms a barrier for the growth or ongrowth of human or animal cells over a period of at least three days, preferably 5 days, particularly preferably 7 days.
- the membrane is produced by the method according to the invention described at the outset.
- the membrane is provided with additional layers in this process or is printed.
- the membrane can be used for material separation, in particular as a filtration membrane.
- filtration membranes with active functions can be realized, the separation efficiency of which can be specifically adjusted through the polarity of the matrix and the structure of the hybrid film structure.
- the membrane according to the invention can fen in surgical interventions in which the risk of postoperative formation of adhesions or scarring exists, in particular when inserting prostheses and Implants, or in pharmaceutical processes as active ingredient carriers, are used.
- the membrane serves as an adhesion barrier or mechanical barrier and prevents cells from neighboring tissues from attaching to the tissue to which the membrane is attached. This results in an effective reduction in scarring, which is particularly relevant in cosmetic surgery.
- a pharmaceutical / therapeutic active substance plaster based on the membrane can be used as an environmentally friendly active substance carrier that can be easily composted after use.
- Example 1 test protocols are given according to which a membrane according to the invention can be produced.
- methods 1-3 variants of Example 1 are described, which show how one can still get to the membrane according to the invention starting from the polymer-sol mixture and the fibers.
- TEOS tetraethoxysilane
- ethanol tetraethoxysilane
- Mixture 1 Polycaprolactone triol (prepared according to Liu et al., Journal of Applied Polymer Science 109 (2008), pp. 1105-1113) is stirred in. This polymer-sol mixture is hereinafter referred to as "mixture 1".
- silica gel fibers manufactured according to Emmert et al., RSC Adv., 2017, 7, 5708, with a diameter of 50 ⁇ m are placed on an ETFE film and flooded with mixture 1.
- the ETFE substrate was inclined at an angle of 25 ° so that the liquid was distributed over the fibers. After one day, the dried film was peeled off as a membrane from the ETFE foil.
- TEOS tetraethoxysilane
- ethanol tetraethoxysilane
- Mixture 2 Polycaprolactone triol (prepared according to Liu et al., Journal of Applied Polymer Science 109 (2008), pp. 1105-1113) is stirred in. This polymer-sol mixture is hereinafter referred to as "mixture 2".
- the paint film applicator had a film width of 225 ⁇ m one day the dried film was peeled off as a membrane from the ETFE foil.
- a mixture 2 is produced analogously to Example 2. Then, according to method 3, the mixture is knife-coated over the fibers placed on an ETFE film.
- Mixture 1 is applied in the liquid-viscous state to a film using a doctor blade. Then fibers are applied to the doctored layer and then another layer is spread over the fibers with a doctor blade. After a certain crosslinking time and after evaporation of solvents, the fiber-reinforced film can be peeled off the substrate.
- Mixture 1 is applied in the liquid-viscous state to a film using a doctor blade. Then fibers are applied to the doctored layer and mixture 1 is flooded over the fibers. After a certain crosslinking time and evaporation of solvents, the fiber-reinforced film can be removed from the substrate.
- Fibers are placed on a film and mixture 1 is applied in the liquid viscous state using a doctor blade. After a certain cross-linking time and evaporation of solvents, the fiber-reinforced film can be removed from the substrate.
- mixtures 1 and 2 can be applied using any of methods 1 to 3.
- FIG. 1 Photograph of two membranes according to the invention.
- FIG. 2 Diagram showing the flexibility of membranes according to the invention.
- FIG. 3 SEM recordings for the degradation of membranes according to the invention.
- Figure 4 Degradation profiles of different membranes.
- FIG. 5 SEM recordings of surfaces of membranes according to the invention.
- FIG. 1 shows fiber-reinforced membranes cut from a DIN A4 sheet and which have already been peeled off from the substrate. These are membranes which were produced according to Example 1 (2-R) and Example 2 (5-R).
- the fiber-reinforced membrane is intrinsically stable, flexible and has a homogeneous structure.
- FIG. 2 shows a diagram from which it can be seen that the flexibility of the membranes produced according to the invention improves with an increasing proportion of organic polymer in the hybrid polymer layer. If twice or five times the mass of organic polymer is used in the manufacturing process based on the inorganic sol, the resulting membrane remains intact even after repeated bending with a small bending diameter. If the mass ratio of organic polymer to inorganic sol in the hybrid polymer layer is only 1: 1, about 75-90% of all membranes break after 10 bending times with a bending diameter of 14 mm.
- the test results which are shown in FIG. 2 relate exclusively to the fiber-reinforced, biodegradable membranes according to the invention. Membranes that are not fiber-reinforced cannot be handled. They break so easily that no bending tests could be carried out.
- FIG. 3 shows three SEM recordings a), b) and c) of a membrane which was produced according to Example 1 and was then wetted with a physiological solution.
- FIG. 3 a which shows a non-degraded film
- the film surface is still very homogeneous.
- the film surface gradually dissolves so that the integrated fibers are exposed (cf. photo in FIG. 3 b).
- the fibers are detached from the membrane (cf. photo in FIG. 3 c).
- the membrane has not contracted, but has retained its original shape. However, the degradation of the membrane continues even after 64 days (not shown).
- FIG. 4 shows degradation profiles of various inventive membranes in phosphate-buffered saline solution over a period of 64 days.
- the square measuring points stand for a membrane that was produced according to Example 1.
- the triangular measuring points have been established for a membrane that was produced according to Example 2.
- the pentagonal and hexagonal measuring points conceal the degradation data of the membranes that were produced according to method 2 with mixtures 1 and 2, respectively.
- FIG. 5 shows SEM recordings of surfaces of two membranes according to the invention. They are largely transparent to visible light and have a smooth surface structure.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Mechanical Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019201550.6A DE102019201550A1 (de) | 2019-02-07 | 2019-02-07 | Biodegradierbare Membran |
PCT/EP2020/052789 WO2020161151A1 (de) | 2019-02-07 | 2020-02-05 | Biodegradierbare membran |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3920990A1 true EP3920990A1 (de) | 2021-12-15 |
Family
ID=69468564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20703734.2A Withdrawn EP3920990A1 (de) | 2019-02-07 | 2020-02-05 | Biodegradierbare membran |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220118162A1 (de) |
EP (1) | EP3920990A1 (de) |
DE (1) | DE102019201550A1 (de) |
WO (1) | WO2020161151A1 (de) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69625822T2 (de) * | 1995-05-01 | 2003-06-05 | Samyang Corp | Implantierbare, bioresorbierbare membran und verfahren zu ihrer herstellung |
DE19853971B4 (de) * | 1998-11-23 | 2011-06-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anorganisch/organische Polysiloxanhybridpolymere und ihre Verwendung |
US6685956B2 (en) | 2001-05-16 | 2004-02-03 | The Research Foundation At State University Of New York | Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications |
-
2019
- 2019-02-07 DE DE102019201550.6A patent/DE102019201550A1/de not_active Ceased
-
2020
- 2020-02-05 WO PCT/EP2020/052789 patent/WO2020161151A1/de unknown
- 2020-02-05 US US17/427,999 patent/US20220118162A1/en active Pending
- 2020-02-05 EP EP20703734.2A patent/EP3920990A1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2020161151A1 (de) | 2020-08-13 |
DE102019201550A1 (de) | 2020-08-13 |
US20220118162A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60212311T2 (de) | Adhäsionsverhindernde Membranen, Verfahren zur Herstellung eines Kollageneinzelstranges, Verfahren und Vorrichtung zur Herstellung eines Kollagenvliesses | |
EP1112095B1 (de) | Biologisch aktive implantate | |
DE60008790T3 (de) | Medizinische verbände enthaltend gelartigen honig | |
EP2688533B1 (de) | Primärauflage für die feuchte wundversorgung und verfahren zu deren herstellung | |
EP3332815B1 (de) | Strukturierte mineralische knochenersatzformkörper | |
DE112015006691B4 (de) | Polyetheretherketon/Nano-Hydroxylapatit-Verbundmaterial für die SLS-Technik und sein Herstellungsverfahren | |
DE602004002908T2 (de) | Postchirurgische Antiadhäsionsschicht bestehend aus Carboxymethylchitosan und Carboxymethylcellulose und ihr Herstellungsverfahren | |
WO2010006708A1 (de) | Kieselsol-material mit mindestens einem therapeutisch aktiven wirkstoff zur herstellung von biologisch degradierbaren und/oder resorbierbaren kieselgel-materialen für die humanmedizin und/oder medizintechnik | |
WO2001055486A1 (de) | Polyelektrolyt-feststoffsystem, verfahren zur herstellung desselben sowie wundverband | |
DE102013221575B3 (de) | Formstabile Knochenersatzformkörper mit verbleibender hydraulischer Aktivität | |
DE69530589T2 (de) | Alginatfasern, herstellung und verwendung | |
EP3920990A1 (de) | Biodegradierbare membran | |
WO2019243187A1 (de) | Verfahren zur herstellung eines antibakteriellen chitosanhaltigen polymers für medizinische zwecke, insbesondere für die wundbehandlung | |
EP4134107A1 (de) | Wundauflage mit einer hydrogelschicht und einer wundkontaktschicht umfassend hyaluronsäure | |
DE10122128A1 (de) | Resorbierbares Patch-Implantat, Verfahren zu seiner Herstellung und Verwendung | |
DE102017217539B4 (de) | Biodegradierbare Fasern, Verfahren zu deren Herstellung und deren Verwendung, sowie diese enthaltende Fasergeflechte oder -filter | |
DE102018211526A1 (de) | Beschichtung für implantierbare medizinische Geräte, Verfahren zu deren Herstellung sowie implantierbares medizinisches Gerät | |
WO2012020127A1 (de) | Sekundäre wässrige dispersionen bioabbaubarer diblockcopolyester,verfahren zu ihrer herstellung und ihre verwendung | |
DE60124214T2 (de) | Thermoplastische Formmassen auf Basis von Polyurethan für orthopädische Zwecke | |
DE202020103361U1 (de) | Mehrschichtprodukt | |
DE202021106754U1 (de) | Ein System zur Regeneration von Hautgewebe unter Verwendung von Nanomedizin und Nanofasern | |
Hum et al. | Bioaktive Glas-Scaffolds beschichtet mit Zein, einem pflanzlichen Protein: Entwicklung und Eigenschaften | |
EP4232102A2 (de) | Resorbierbare deckmembran zur medizinischen wundflächenbehandlung | |
DE102014108727B4 (de) | Beschichtete Erzeugnisse für den oralen Bereich, Verwendung und Beschichtungsverfahren für Chitosan | |
EP4335466A1 (de) | Zusammensetzung zur herstellung eines knochenersatzmaterials, verfahren zur herstellung eines pharmazeutischen wirkstoffträgers, pharmazeutischer wirkstoffträger sowie dessen verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210805 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220720 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20221201 |